Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia

Margaret L. MacMillan, Qing Cao, Martin Felices, Megan Larson, David McKenna, Meera Srikanthan, John E Wagner

Blood (2024) 144 (Supplement 1): 3490.

https://doi.org/10.1182/blood-2024-205404

Published: 2024

Journal Articles

A Pan-Cancer Single-Cell Transcriptomic Atlas of Natural Killer (NK) Cells Reveals Intrinsic and Extrinsic Mediators of NK Cell Anti-Tumor Functions

John R Lozada, Atef Ali, Abderrahman Day, Jacob A Myers, Ella Boytim, Hannah Bergom, Nicholas Zorko, Martin Felices, Jeffrey S Miller, Justin Hwang, Frank Cichocki

Blood (2023) 142 (Supplement 1): 2547.

https://doi.org/10.1182/blood-2023-187347

Published: 2023

Journal Articles

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

Blood (2022) 140 (23): 2451–2462.

https://doi.org/10.1182/blood.2021015184

Published: 2022

Includes: Supplemental data

Journal Articles

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Zachary Davis, Frank Cichocki, Martin Felices, Hongbo Wang, Peter Hinderlie, Mark Juckett, Joseph Maakaron, Gregory I. Berk, Bryan Hancock, John Goulding, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 10288–10289.

https://doi.org/10.1182/blood-2022-168981

Published: 2022

Journal Articles

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

Aimee Merino, Hayden Hamsher, Daniel Mansour, Gregory I. Berk, Martin Felices, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 8851–8852.

https://doi.org/10.1182/blood-2022-162566

Published: 2022

Journal Articles

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

Blood (2021) 138 (Supplement 1): 407.

https://doi.org/10.1182/blood-2021-148654

Published: 2021

Journal Articles

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Rose Wangen, Dixie Lewis, RN,BA, JoAnn Knox, Martin Schroeder, Martin Felices, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-136398

Published: 2020

Journal Articles

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Karrune Woan, MD PhD, Zachary Davis, PhD BS, Greg Bonello, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Tom Lee, PhD, Martin Felices, PhD, Bruce Walcheck, PhD, Bruce R. Blazar, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 57–58.

https://doi.org/10.1182/blood-2020-137138

Published: 2020

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

Cyclin-Dependent Kinases (CDK) Signaling Blockade Potentiates NK Cell Mediated Cytotoxicity Against Acute Myelogenous Leukemia

Hyun Don Yun, MD, Dawn Schirm, Martin Felices, PhD, Jeffrey S. Miller, MD, Craig E. Eckfeldt, MD PhD

Blood (2018) 132 (Supplement 1): 4538.

https://doi.org/10.1182/blood-2018-99-113004

Published: 2018

Journal Articles

Enhancing Human NK Cell Function and Specificity for Cancer Immunotherapy

Pomeroy Emily, Hunzeker John, Kluesner Mitchell, Crosby Margaret, Laura Bendzick, Jeffrey S. Miller, MD, Beau Webber, PhD, Melissa A. Geller, Martin Felices, PhD, Tim Starr, Branden S Moriarity, PhD

Blood (2018) 132 (Supplement 1): 2044.

https://doi.org/10.1182/blood-2018-99-120173

Published: 2018

Journal Articles

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Emily Chiu, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Sarah Cooley, MD, Helen Chu, PhD, Moyar Q. Ge, PhD, Ryan Bjordahl, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 729.

https://doi.org/10.1182/blood-2018-99-112202

Published: 2018

Journal Articles

CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia

Upasana Sunil Arvindam, MSc, BSc, Paulien van Hauten, MSc-MD, Caroline Hallstrom, BS, Daniel A. Vallera, PhD, Harry Dolstra, PhD, Jeffrey S. Miller, MD, Martin Felices, PhD

Blood (2018) 132 (Supplement 1): 1454.

https://doi.org/10.1182/blood-2018-99-117150

Published: 2018

Journal Articles

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Martin Felices, PhD, Craig E. Eckfeldt, MD PhD, Todd R Lenvik, Behiye Kodal, Alexander J. Lenvik, Laura Bendzick, Caitlin Ryan, Melissa A. Geller, Sarah Cooley, MD, Daniel J. Weisdorf, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 4465.

https://doi.org/10.1182/blood.V130.Suppl_1.4465.4465

Published: 2017

Journal Articles

Engineering of Trispecific Molecule That Induces Natural Killer Cell Expansion While Mediating CD133-Specific Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

Jörg Uwe Schmohl, MD, Martin Felices, PhD, Jeffrey S. Miller, MD, Dan Vallera, PhD

Blood (2016) 128 (22): 3518.

https://doi.org/10.1182/blood.V128.22.3518.3518

Published: 2016

Journal Articles

A Novel HIV Envelope Bi-Specific Killer Engager Enhances Natural Killer Cell Mediated ADCC Responses Against HIV-Infected Cells

Zachary B. Davis, PhD BS, Todd Lenvik, Louis Hansen, Martin Felices, PhD, Sarah Cooley, MD, Dan Vallera, PhD, Ashley T. Haase, MD, Richard A. Koup, MD, Daniel Douek, MD, Timothy Schacker, MD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 2517.

https://doi.org/10.1182/blood.V128.22.2517.2517

Published: 2016

Journal Articles

Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity

Martin Felices, PhD, Alexander Lenvik, Sami Chu, Ron McElmurry, Sarah Cooley, MD, Jakub Tolar, MD PhD, Bruce R. Blazar, MD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 551.

https://doi.org/10.1182/blood.V128.22.551.551

Published: 2016

Journal Articles

Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant

Rohtesh S. Mehta, MD MPH, MS, Rose Wangen, Frank Cichocki, PhD, Martin Felices, PhD, Xianghua Luo, PhD, Daniel J. Weisdorf, MD, Michael R. Verneris, MD, Jeffrey S. Miller, MD, Sarah Cooley, MD

Blood (2016) 128 (22): 515.

https://doi.org/10.1182/blood.V128.22.515.515

Published: 2016

Journal Articles

Fewer Circulating Natural Killer Cells 28 Days after Double Cord Blood Transplantation (dUCBT) Predicts Inferior Survival and IL-15 Response

Bergerson Rachel, PhD, Robin Williams, MD MS, Hongbo Wang, MD PhD, Ryan Shanley, MS, Gretchen Hoff, Alyssa Kerber, Sarah Cooley, MD, Julie Curtsinger, PhD, Martin Felices, PhD, Jeffrey S. Miller, MD, Michael R. Verneris, MD

Blood (2016) 128 (22): 2231.

https://doi.org/10.1182/blood.V128.22.2231.2231

Published: 2016

Journal Articles

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

Martin Felices, PhD, Dhifaf Sarhan, PhD, Ludwig Brandt, Karolin Guldevall, Ron McElmurry, Alexander Lenvik, Sami Chu, Jakub Tolar, MD PhD, Elizabeth Taras, Stephen R Spellman, MS, Erica D. Warlick, MD, Michael R. Verneris, MD, Sarah Cooley, MD, Daniel Weisdorf, MD, Bruce R. Blazar, MD, Bjorn Onfelt, PhD, Dan Vallera, PhD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 4291.

https://doi.org/10.1182/blood.V128.22.4291.4291

Published: 2016

NARROW

TCRα/β Depleted Mobilized Pbscs without Calcineurin Inhibitors in Patients with Fanconi Anemia

A Pan-Cancer Single-Cell Transcriptomic Atlas of Natural Killer (NK) Cells Reveals Intrinsic and Extrinsic Mediators of NK Cell Anti-Tumor Functions

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Cyclin-Dependent Kinases (CDK) Signaling Blockade Potentiates NK Cell Mediated Cytotoxicity Against Acute Myelogenous Leukemia

Enhancing Human NK Cell Function and Specificity for Cancer Immunotherapy

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia

Second-Generation Camelid Trike Induces Improved NK Cell Mediated Targeting of AML in Pre-Clinical Models

Engineering of Trispecific Molecule That Induces Natural Killer Cell Expansion While Mediating CD133-Specific Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)

A Novel HIV Envelope Bi-Specific Killer Engager Enhances Natural Killer Cell Mediated ADCC Responses Against HIV-Infected Cells

Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity

Adaptive NK Cell Expansion Is Associated with Reduced Relapse of Lymphoid Malignancies after Autologous Hematopoietic Cell Transplant

Fewer Circulating Natural Killer Cells 28 Days after Double Cord Blood Transplantation (dUCBT) Predicts Inferior Survival and IL-15 Response

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only